SutroVax is focused on developing innovative vaccines to combat bacterial infections, particularly targeting invasive pneumococcal disease, Group A Streptococcus, periodontitis, and Shigella. Their lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine (PCV) designed to cover a wide range of serotypes responsible for pneumococcal disease, which remains a significant public health concern despite existing vaccines. VAX-24 has received FDA Breakthrough Therapy designation, highlighting its potential to significantly reduce morbidity and mortality associated with invasive pneumococcal disease. Following VAX-24, SutroVax is advancing VAX-31, a 31-valent PCV candidate aimed at addressing over 90% of circulating pneumococcal strains in the U.S.

The company employs advanced synthetic techniques, particularly their XpressCF™ cell-free protein synthesis platform, to create high-fidelity vaccines. This technology allows for the production of complex protein antigens that can effectively elicit immune responses while overcoming the bacteria's defense mechanisms. SutroVax is also developing additional vaccine candidates, including VAX-A1 for Group A Strep, VAX-PG for periodontitis, and VAX-GI for Shigella, all of which are in various stages of preclinical and clinical development. Their approach aims to provide broad-spectrum protection against bacterial diseases that currently lack effective vaccines, addressing the growing challenge of antibiotic resistance and the need for innovative preventive measures.

United States

SutroVax is a biopharmaceutical company that focuses on delivering best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious infectious diseases, with a lead product candidate targeting invasive pneumococcal infections.

SutroVax

Company Details